We had a chance to speak with Darlene last week, and after listening to the recent 1Q earnings release conference call, we're somewhat convinced that both the asthma and anemia drugs are may follow the fate of PRS-050: discontinuation after proof-of-concept data
ECYT will be presenting this weekend. They have a new and improved product. CASH is market value plus research on top of it. Next week it will pass resistance to above 4.00, after that it is easy ride ..
Sentiment: Strong Buy